Imperial College London
Dr Tara Mangal

DrTaraMangal

Faculty of Medicine, School of Public Health

Research Fellow
 
 
 
//

Contact

 

+44 (0)20 7594 3290t.mangal

 
 
//

Location

 

Medical SchoolSt Mary's Campus

//

Summary

 

Publications

Citation

BibTex format

@article{Mangal:2014:10.1016/S2214-109X(13)70168-2,
author = {Mangal, TD and Aylward, RB and Mwanza, M and Gasasira, A and Abanida, E and Pate, MA and Grassly, NC},
doi = {10.1016/S2214-109X(13)70168-2},
journal = {The Lancet Global Health},
pages = {E90--E97},
title = {Key issues in the persistence of poliomyelitis in Nigeria: a case-control study},
url = {http://dx.doi.org/10.1016/S2214-109X(13)70168-2},
volume = {2},
year = {2014}
}
Download

RIS format (EndNote, RefMan)

TY  - JOUR
AB  - BackgroundThe completion of poliomyelitis eradication is a global emergency for public health. In 2012, more than 50% of the world's cases occurred in Nigeria following an unanticipated surge in incidence. We aimed to quantitatively analyse the key factors sustaining transmission of poliomyelitis in Nigeria and to calculate clinical efficacy estimates for the oral poliovirus vaccines (OPV) currently in use.MethodsWe used acute flaccid paralysis (AFP) surveillance data from Nigeria collected between January, 2001, and December, 2012, to estimate the clinical efficacies of all four OPVs in use and combined this with vaccination coverage to estimate the effect of the introduction of monovalent and bivalent OPV on vaccine-induced serotype-specific population immunity. Vaccine efficacy was determined using a case-control study with CIs based on bootstrap resampling. Vaccine efficacy was also estimated separately for north and south Nigeria, by age of the children, and by year. Detailed 60-day follow-up data were collected from children with confirmed poliomyelitis and were used to assess correlates of vaccine status. We also quantitatively assessed the epidemiology of poliomyelitis and programme performance and considered the reasons for the high vaccine refusal rate along with risk factors for a given local government area reporting a case.FindingsAgainst serotype 1, both monovalent OPV (median 32·1%, 95% CI 26·1–38·1) and bivalent OPV (29·5%, 20·1–38·4) had higher clinical efficacy than trivalent OPV (19·4%, 16·1–22·8). Corresponding data for serotype 3 were 43·2% (23·1–61·1) and 23·8% (5·3–44·9) compared with 18·0% (14·1–22·1). Combined with increases in coverage, this factor has boosted population immunity in children younger than age 36 months to a record high (64–69% against serotypes 1 and 3). Vacci
AU  - Mangal,TD
AU  - Aylward,RB
AU  - Mwanza,M
AU  - Gasasira,A
AU  - Abanida,E
AU  - Pate,MA
AU  - Grassly,NC
DO  - 10.1016/S2214-109X(13)70168-2
EP  - 97
PY  - 2014///
SN  - 2214-109X
SP  - 90
TI  - Key issues in the persistence of poliomyelitis in Nigeria: a case-control study
T2  - The Lancet Global Health
UR  - http://dx.doi.org/10.1016/S2214-109X(13)70168-2
UR  - http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000336424300015&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=1ba7043ffcc86c417c072aa74d649202
UR  - https://www.thelancet.com/journals/langlo/article/PIIS2214-109X(13)70168-2/fulltext#seccestitle10
VL  - 2
ER  -
Download